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Received October 7, 2013; accepted May 12, 2014AbstractInfluenza treatment and prophylaxis with oseltamivir are critically important in reducing the morbidity and mortality of patients in chronic
psychiatric facilities. Abnormal behavior, delusions, perceptual disturbances, mania, and depression have all been reported as oseltamivir-related
psychiatric side effects. We hereby report two chronic schizophrenia patients in Taiwan manifesting psychiatric instability who were being
treated with oseltamivir for suspected influenza infection, and further discuss other potential contributing factors. The possibility that oseltamivir
can cause psychotic or affective symptoms suggests that additional caution is necessary for its use in patients with an established psychiatric
diagnosis.
Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
Keywords: influenza; oseltamivir; psychiatric symptoms; schizophrenia1. Introduction
Psychiatric patients hospitalized in a chronic ward setting
are at a high risk for infectious diseases, especially those
which are highly contagious such as influenza.1 Infection
control measures, as well as immediate treatment and appro-
priate prophylaxis with antiviral agents such as oseltamivir,
are of paramount importance in chronic mental health facil-
ities to prevent an influenza outbreak and to minimize
morbidity and mortality of those infected.2,3 We hereby report
two cases of chronic schizophrenia patients in Taiwan mani-
festing acute exacerbation of psychiatric symptoms while
being treated with oseltamivir for suspected influenza B virusConflicts of interest: The authors declare that there are no conflicts of interest
related to the subject matter or materials discussed in this article.
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and treatment recommendations.2. Case reports
There were a total of 100 patients in this chronic psychiatric
ward; 40 female patients lived on the first floor with four
patients/room and 60 male patients lived on the second floor
with five patients/room. These 100 patients shared the same
public spaces such as the dining areas, recreational quarters,
and exercise spaces, although each patient room was equipped
with a toilet.
The two cases presented below lived in the same room for 4
days with an index case of influenza B infection confirmed by
rapid test for influenza antigen. This index case was a 49-year-
old single man with chronic schizophrenia and without a
history of systemic disease. For purposes of clarity in disease
course description, we designated the day on which both of
our cases first experienced onset of fever as Day 1. Tracingociation. All rights reserved.
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home leave from Day 13 to Day 8, wherein he had spent
time with a family member with upper respiratory infection
symptoms. He returned to the psychiatric ward on Day 8 and
lived with the two cases in the same room for 4 days from Day
8 to Day 5. The index case developed a fever and upper
respiratory symptoms since Day 5 and was transferred to a
single room. He later developed secondary pneumonia and
was transferred to the intensive care unit with endotracheal
intubation on Day 1.
Five days after the fever episode of the index case, both
cases developed fever exceeding 38C, headache, and promi-
nent upper respiratory symptoms. Influenza B infection was
strongly suspected in both cases, although the results of rapid
tests for influenza antigens were negative. According to
Taiwan Centers for Disease Control (CDC) regulations for
treatment of influenza-like-illness, oseltamivir was prescribed
for both cases due to the close contact history and also due to
the history of diabetes mellitus in Case 1.2.1. Case 1Mr. Y, a 41-year-old single man, was diagnosed with
schizophrenia at the age of 19 years, with presentations of
auditory hallucinations with a voice commenting, persecutory
delusion, violent behavior, and significant academic function
deterioration. He had been a patient on our ward for 11 years,
suffering psychotic symptoms which were controlled with
clozapine 400 mg/d. Additionally, social withdrawal and af-
fective flattening were prominent. The patient also had hy-
pertension and type 2 diabetes mellitus under medication
control with olmesartan 20 mg QD, metformin 500 mg QD,
and glimepiride 2 mg BID.
On the 1st day of suspected influenza infection, with
symptoms of fever, sore throat, rhinorrhea, headache, and
muscle soreness, clozapine was decreased to 300 mg/d and
further dropped to 150 mg/d on Day 3 to attenuate the sedative
effect and prevent sialorrhea-related aspiration. Oseltamivir
75 mg BID for 5 days was prescribed beginning on Day 2.
Thereafter, delusion with paranoid and grandiose content
associated with agitation developed on Day 5. He became
uncooperative in his compliance with treatment procedures,
such as intravenous catheter insertion and quarantine in a
single room, and required frequent physical restraints. Clo-
zapine was then titrated up to 200 mg on Day 5, 250 mg on
Day 6, and 300 mg on Day 7. Thereafter, his psychotic
symptoms rapidly improved and disappeared on Day 9. His
fever subsided on Day 4 and upper respiratory symptoms
resolved completely on Day 14.2.2. Case 2Mr. L, a 71-year-old married man without chronic phys-
ical illness, was diagnosed with schizophrenia at the age of
40 years, with persecutory and religious delusions, auditory
hallucinations, and violent behavior. He had been admitted
for 7 years and psychotic symptoms were under controlwith quetiapine 200 mg/d without prominent negative
symptoms.
His symptoms of fever, headache, sore throat, and rhinor-
rhea had developed on Day 1. On Day 2, the same oseltamivir
regimen was prescribed and quetiapine was decreased to
100 mg/d to reduce its sedative effect. On Day 4, hypomanic
symptoms with elevated mood, flight of idea, hypertalkativity,
and hyperactivity disturbed Mr. L's infection control pro-
cedures. Quetiapine 200 mg/d was resumed on Day 7 and the
hypomanic symptoms resolved on Day 10. Ultimately, his
fever subsided on Day 5 and upper respiratory symptoms
cleared on Day 15.
3. Discussion
Psychiatric patients hospitalized in chronic wards are highly
susceptible to influenza infections that cause substantial
morbidity and mortality.4 Oseltamivir, a neuraminidase inhibi-
tor, is extensively used in the treatment and prophylaxis of
suspected influenza A and B virus infection.5 Oseltamivir-
related neuropsychiatric events of abnormal behaviors, de-
lusions, and perceptual disturbances have been reported in
Japan, the United States, and other countries.6 Furthermore,
there were case reports indicating that oseltamivir may induce
mania7 and depression.8 This evidence primarily stemmed from
case reports or postmarketing surveys among patients without
previous psychiatric disorders. The possibility that oseltamivir
could cause psychiatric symptoms requires its cautious use in
patients with an established psychiatric disorder.
Oseltamivir has earlier been shown to affect neuron func-
tioning and behavior in animals.9,10 Specifically, oseltamivir
may cause psychiatric side effects by influencing dopaminergic
neurotransmission. First, oseltamivir may increase dopamine
release from the presynaptic neurons. Significantly elevated
levels of dopamine in the medial prefrontal cortex after intra-
peritoneal administration of oseltamivir has been reported in
rats.11 Second, oseltamivir may enhance agonist-induced
dopamine D2 receptor activity. By inhibiting neuraminidases
that are also sialidases, oseltamivir reduces the hydrolysis of
sialic acid linkage to glycolipids. Subsequently, these sialo-
glycolipids boost the effect of increased D2 receptor activity by
agonists. This mechanism has been implicated in an animal
study linking oseltamivirwith abnormal behavior.12Oseltamivir
may assert a similar influence on the human nervous systems
and cause prominent psychiatric symptoms. Further in-
vestigations by human experimental studies are indicated.
Delusions, hallucinations, and manic/hypomanic manifes-
tations have also been related to influenza infection with or
without encephalitis.13e16 The possibility of influenza infec-
tion itself precipitating the psychiatric instability observed in
our cases further complicated the treatment of influenza in
chronic psychiatric patients. On the one hand, oseltamivir may
potentially worsen psychiatric symptoms; on the other hand,
possible influenza-induced exacerbations of psychiatric
symptoms warrant oseltamivir treatment.
Decreasing the antipsychotic dosage during influenza
treatment might also contribute to psychiatric instability.
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may cause withdrawal symptoms related to cholinergic crisis
and manifest as agitation, abnormal movements, and wors-
ening of psychotic symptoms.17 This “rebound psychosis” was
demonstrated to be related to the increased binding of
endogenous dopamine to the D2 receptor after clozapine
withdrawal.18 Clozapine, quetiapine, olanzapine, zotepine, and
risperidone have been associated with an increased risk of
pneumonia in schizophrenia patients from a nested case-
econtrol study utilizing Taiwan's National Health Insurance
Research Database.19 This is one of the reasons we tapered
down the antipsychotics. The other reasons were to prevent
oversedation and aspiration related to extrapyramidal side
effects or clozapine-induced sialorrhea.
The obvious emergence of psychotic and hypomanic
symptoms in our chronically stable patients would have
caused difficulty in the proper treatment of influenza and
related physical symptoms without the aid of frequent physical
restraints. Fortunately, the psychiatric symptoms remitted
promptly in both patients after titrating up the antipsychotics
close to the original daily dose.
In conclusion, to our knowledge, these are the first case
reports addressing psychiatric instability during oseltamivir
treatment among chronic psychiatric patients. Although
influenza infection itself or the decrement of antipsychotics
may also be contributing factors, this nevertheless highlights
the need for vigilant use of oseltamivir in this specific
population.
Currently, there are no standard guidelines regarding anti-
psychotic dosage adjustment when oseltamivir is used for
chronic psychiatric patients. Our recommendation is that an-
tipsychotics should be continued at the original dosage level
during oseltamivir treatment to prevent psychiatric destabili-
zation, which may sequentially impede the management of
physical symptoms. If deterioration of the patients' physical
condition is suspected to be related to antipsychotics, the
dosage should be cautiously tapered down temporarily and
resumed to the original dosage as soon as possible.
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